ANIRACETAM

• Molar weight : 219.237 g/mol
• Molecular Formula: C12H13NO3
• Sequence: Non-Peptide

DESCRIPTION

Aniracetam employs a similar method of action to other racetams. It has been shown to specifically stimulate the AMPA receptor site. The AMPA receptor is the most common glutamate- activated receptor associated with the Central Nervous System and its functions. AMPA receptors play a role in learning and memory formation. Aniracetam seems to have a higher affinity with the AMPA receptors than other racemic compounds. Another interesting action of Aniracetam is the observed anxiety- reducing effects. It completes this action without causing sedation and the anxiolytic benefit of the substance has been extensively studied in animal models. This anxiolytic response is believed to be caused in part, by activation of the D2 and D3 dopamine receptors. Nicotinic Ach receptor activation is also believed to contribute to anxiolytic effects and nootropic effects as well. Additionally, Aniracetam seems to enact on the 5-HTP(2a) receptor which helps to process Serotonin and may further advance anxiolytic/ antidepressant functions.

PROTOCOL

• Content & Potency: 375mg capsules provided in a quantity of 60.
• Suggested dosage: Take two capsules by mouth every morning with food for 30 days.

CLINICAL RESEARCH

Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined withCholinesterase Inhibitors, in Patients with Cognitive Impairment: AComparative Open Study*

In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEls), in terms of several neuropsychological parameters, in a considerable number of patients with dementia. In our prospective, open-label study, we enrolled a total of 276 patients (mean age 71 ± 8 years, 95 males) with cognitive disorders. Our study population comprised four groups: no treatment group (n = 75), aniracetam monotherapy group (n = 58), ChEIs monotherapy group (n = 68), and group of combined treatment (n = 68). Patients were examined with validated neuropsychological tests at baseline, 3, 6, and 12 months of treatment. In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months. In patients treated with ChEIs, we observed a significant cognitive deterioration at 12 months. The comparison between aniracetam and ChEls in patients with relatively mild dementia (15 ≤ MMSE ≤ 25) revealed a significantly better cognitive performance with aniracetam at 6 months and improved functionality at 3 months. Comparing aniracetam monotherapy with combined treatment in the same population, aniracetam performed better in the cognitive scale at 6 months, and displayed a notable tendency for enhanced mood at 12 months and improved functionality at 6 months. Conclusions: Our findings indicate that aniracetam (a noo – tropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity. It preserved all neuropsychological parameters for at least 12 months, and seemed to exert a favorable effect on emotional stability of demented patients.

Here are some reliable sources for information on ANIRACETAM:

1. Examine.com: Examine.com is an independent and unbiased source of information on supplements and nutrition. Their Aniracetam page provides a comprehensive overview of the chemical, its effects, and research studies on its usage. Link: https://examine.com/supplements/aniracetam/
2. ScienceDirect: ScienceDirect is a scientific database that provides research papers, books and reference material on various topics, including Aniracetam. Link: https://www.sciencedirect.com/topics/medicine-and-dentistry/aniracetam
3. Wikipedia: The Wikipedia article on Aniracetam provides an overview of the chemical, its properties, and its applications. Link: https://en.wikipedia.org/wiki/Aniracetam

These resources should provide you with a good starting point for your research on Aniracetam. However, always remember to double-check and verify the information you find from multiple sources to ensure accuracy and reliability. It is also recommended to consult with a healthcare professional before taking any supplements.

ANIRACETAM Research

Here are some examples of research studies that have been conducted on the peptide ANIRACETAM:

1. A study on the effects of ANIRACETAM on cognitive performance and mood in healthy adults: https://www.ncbi.nlm.nih.gov/pubmed/18598174
2. A review article on the pharmacology and therapeutic potential of ANIRACETAM: https://www.ncbi.nlm.nih.gov/pubmed/16155615
3. A study on the neuroprotective effects of ANIRACETAM in a rat model of traumatic brain injury: https://www.ncbi.nlm.nih.gov/pubmed/29308900
4. A research article describing the potential use of ANIRACETAM in the treatment of Alzheimer’s disease: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564632/
5. A study on the effects of ANIRACETAM on depression and anxiety in patients with major depressive disorder: https://www.ncbi.nlm.nih.gov/pubmed/27723543

Please note that this is not an exhaustive list and there may be other studies that have been conducted on ANIRACETAM.